AlbuSorb™ Albumin Depletion Kit
- Removes >90% albumin from 30 mg albumin/ml sample
- Affinity-type equivalence, virtually no cross-reactivity with other proteins
- Bind and elute procedure - simply weigh powder, condition the sample, centrifuge and/or filter, and recover the albumin depleted serum
- Economical new surface technology, not based on affinity chromatography
- Mild conditions maintain tertiary structure of proteins and simple transfer to secondary analysis
- The albumin depleted filtrate retains the enzymatic and biological activity
- Removes albumin from samples such serum, plasma and from species including human, mouse, sheep, bovine, goat, rat, and calf
Albusorb™ is an albumin depletion reagent supplied as a kit with necessary buffers. With 25ul of starting sample, the yield of albumin depleted serum protein is 0.1-0.2 milligrams. Albusorb™ binds albumin from serum or plasma and is compatible with downstream proteomics methods such as protein array pixelation ,1D and 2D gel electrophoresis, LC/MS, and MALDI-TOF MS. Samples are also prepared for biomarker discovery, toxicological studies for new drugs, enzyme assays, protein profiling using SELDI analysis and cytokines research.
AlbuSorb™ binds to albumin, and serum proteins flow through. Removal of albumin allows enhanced detection of low abundance proteins. AlbuSorb™ comes from a silica-based, separation platform utilizing a new combination of surface microenvironments substituted with low molecular substrates that feature drug-binding motifs. Unlike immuno-affinity, the surfaces utilized are disposable eliminating cycle to cycle variance and cross-contamination.
Biotech Support Group also has AlbuVoid™ for albumin depletion plus low abundance serum protein enrichment.
Click here for the Albusorb™ Product Sheet
Effects of Nobiletin on PhIP-Induced Prostate and Colon Carcinogenesis in F344 Rats Authors: Ming Xi Tang, Nutrition and cancer. 02/2011; 63(2):227-33
Apolipoprotein CIII and Ljungan virus in diabetes Holmberg, Rebecka Doctoral Thesis 26-May-2010
Development of different analysis platforms with LC-MS for pharmacokinetic studies of protein drugs. Lu Q, Zheng X, Anal Chem. 2009 Nov 1;81(21):8715-23.





